Recent Press Releases

Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder

05/17/17 - Top Line Results Expected in 3Q 2017 GERMANTOWN, Md., May 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation treatments for nervous system diseases, today announce... More

Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update

05/10/17 - Phase 2 MDD clinical trial results expected in 3Q17, Extended runway of cash into 3Q18 GERMANTOWN, Md., May 10, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation trea... More

Neuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury

04/12/17 - Investigating New Patient Cohort with Cervical Injury GERMANTOWN, Md., April 12, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based o... More
More

Upcoming Events

2017 Neuralstem, Inc. Annual Meeting of Shareholders

Thursday, June 22, 2017 8:00 a.m. ET
More
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
Share PageShare Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts
Financial Tear SheetFinancial Tear Sheet